<DOC>
	<DOC>NCT02437916</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.</brief_summary>
	<brief_title>Safety Study of AMG 228 to Treat Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<criteria>Subject must have a pathologically documented, definitively diagnosed, advanced solid tumor Adequate hematological, renal, hepatic, and coagulation laboratory assessments Active autoimmune disease, history of autoimmune disease Treatment with immune modulators including Use of warfarin, factor Xa inhibitors, or direct thrombin inhibitors Antitumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days Major surgery within 28 days of study day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Non-small Cell Lung Cancer (NSCLC)</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Head and Neck</keyword>
	<keyword>Transitional Cell Carinoma (TCC)</keyword>
	<keyword>Bladder</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Colorectal Cancer (CRC)</keyword>
</DOC>